Drug discovery group Evgen Pharma said it is pleased with its progress on treatments under development. The business focuses on treatments for cancer, strokes and Multiple Sclerosis. The company also revealed encouraging data in recent preliminary reports from pre-clinical programmes in triple negative breast cancer, glioblastoma and ischaemic stroke.
Chief executive Stephen Franklin said: “We were delighted with the positive breast cancer interim data showing good tolerability and efficacy in this very difficult to treat patient population and are hopeful that these trends will be maintained in the final analysis…we are excited about the near-term prospects of the company.”
See the article in full at TheBusinessDesk.com